Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases. The company employs proprietary technology to design DNA plasmids, which function like software that cells can download to produce specific proteins targeting diseases. These plasmids are delivered using investigational CELLECTRA devices, which apply brief electrical pulses via electroporation to facilitate entry into cells without chemical adjuvants, lipid nanoparticles, or viral vectors. This platform enables targeted immunotherapies that stimulate T cells and antibodies for immune responses against cancers and viruses. Inovio Pharmaceuticals, Inc. advances its pipeline through clinical research, focusing on innovative next-generation therapies in these critical therapeutic areas. Headquartered in Pennsylvania, the company plays a significant role in the biotechnology sector by pioneering DNA-based solutions for unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Jacqueline E. Shea Ph.D.

Employees

134

Headquarters

Plymouth Meeting, PA, United States

Website

www.inovio.com